Early Development Global Regulatory Lead

<br/> <!-- --> <!-- --> <!-- --> <div> <!-- --> <div> <br/> <div> <em>Join us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to treat patients across dozens of severe autoimmune diseases.<br/><br/></…